COMMUNIQUÉS West-GlobeNewswire

Koç University Hospital, a Koç Healthcare Institution, is Named Türkiye’s Top Hospital and Ranked Among the Newsweek–Statista World’s Best Hospitals 2026
04/03/2026
ISTANBUL, March 04, 2026 (GLOBE NEWSWIRE) -- Koç University Hospital a leading institution of Koç Healthcare has set the national benchmark for excellence in healthcare. In the recently announced 2026 edition of [...]
Baylor Genetics to Highlight New Data and Product Innovations at 2026 ACMG Annual Clinical Genetics Meeting
04/03/2026
Company’s exhibit theater presentation will highlight multiomic and multimodal innovations in rare disease diagnostics HOUSTON, March 04, 2026 (GLOBE NEWSWIRE) -- Baylor Genetics , a leading diagnostic genomics partner [...]
FemPulse Pivotal Study Selected For Presentation at the American Urological Association Annual Conference
04/03/2026
SAN FRANCISCO, March 04, 2026 (GLOBE NEWSWIRE) -- FemPulse™, a bioelectronic medical technology company with first application overactive bladder (OAB), announced today that the Company’s pivotal clinical study was [...]
Press Release: Filing of an amendment to the French “Document d’Enregistrement Universel” containing the Annual Financial Report
04/03/2026
Filing of an amendment to the French “Document d’Enregistrement Universel” containing the Annual Financial Report Paris, March 4, 2026 . Sanofi announces today the filing of an amendment to its “Document d’ [...]
CervoMed Announces Selection of Formulation and Dosing Regimen for Planned Phase 3 Trial in Patients with Dementia with Lewy Bodies
04/03/2026
Bioavailability data recently obtained from Phase 1 study with a stable crystal form of neflamapimod manufactured using a new, controlled manufacturing process Pharmacokinetic profile of the new, stable crystal form of [...]
Fennec Pharmaceuticals Announces Clinical Research Collaboration with Tampa General Hospital Cancer Institute
04/03/2026
Study is Real-World Evaluation of the Clinical Utility of Sodium Thiosulfate Injection (PEDMARK®) in Reducing the Risk of Ototoxicity in Adolescent and Young Adult (AYA) and Adult Patients with Non-Metastatic Solid [...]
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
04/03/2026
BOSTON, March 04, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, [...]
Rezolute to Participate in the Citizens Life Sciences Conference
04/03/2026
REDWOOD CITY, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of [...]
Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate Updates
04/03/2026
On track to submit Conditional Marketing Authorization for iopofosine I 131 to European Medicines Agency in Q3 2026 for potential 2027 EU commercialization as a treatment for Waldenström Macroglobulinemia Initiated [...]
Clover Health Moves from Pledge to Production, Becomes The First Payer Live on a CMS Aligned Network
04/03/2026
Clover Health's early adoption of real-time patient access to claims data on a CMS Aligned Network is made possible by underlying infrastructure powered by Counterpart Health. WILMINGTON, Del., March 04, 2026 (GLOBE [...]
Microbot Medical® Aligns with Recently Adopted Policy of the Largest U.S.-Based Medical Association to Expand Protection for Healthcare Professionals from Ionizing Radiation
04/03/2026
LIBERTY® Endovascular Robotic System’s Capability to Reduce Radiation Exposure Appeals to Hospitals and Healthcare Providers HINGHAM, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), [...]
Boundless Bio to Participate in the Leerink Global Healthcare Conference
04/03/2026
SAN DIEGO, March 04, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with [...]
Clearmind Medicine Moving Forward to the Next Stage of Its Clinical Trial Following Data and Safety Monitoring Board Approval
04/03/2026
The approval was granted based on additional topline positive safety results reinforcing favorable profile of CMND-100 in ongoing Phase I/IIa clinical trial Vancouver, Canada, March 04, 2026 (GLOBE NEWSWIRE) -- [...]
Glucose Health Expands Retail Distribution to 2,500+ Stores, Launches National Advertising Campaign
04/03/2026
BENTONVILLE, Ark., March 04, 2026 (GLOBE NEWSWIRE) -- Glucose Health, Inc. (OTC: GLUC), a consumer-health company specializing in soluble-fiber nutrition products that support healthy glucose metabolism and metabolic [...]
Alterity Therapeutics Appoints Daniel O. Claassen, M.D., M.S., as Chief Medical Advisor
04/03/2026
– Neurology and Movement Disorder Specialist Adds Deep Clinical and Development Expertise – MELBOURNE, Australia and SAN FRANCISCO, March 04, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“ [...]
Dyadic and Fermbox Bio Launch First Product Under Expanded Collaboration: Animal-Origin-Free Recombinant DNase I (RNase-Free)
04/03/2026
JUPITER, Fla. and BENGALURU, India, March 04, 2026 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company producing precision- [...]
NervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP, Patient Advocacy and Clinical Affairs
04/03/2026
VANCOUVER, British Columbia, March 04, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class [...]
Entera Bio Submits Streamlined Phase 3 Protocol to Initiate Registrational Program for EB613 in Postmenopausal Women with Osteoporosis
04/03/2026
Phase 3 study designed with total hip BMD primary endpoint assessed at 12 months, rather than at 24 months EB613 single tablet final commercial formulation (Next-Gen EB613) replaces multi-tablet EB613 as Phase 3 [...]
Can-Fite’s Namodenoson Successfully Meets Primary Endpoint in Phase 2a Pancreatic Cancer Study
04/03/2026
Ramat Gan, Israel, March 04, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs for the [...]

Pages